Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioMarin Pharmaceutical stock in Canada | $77.3

Own BioMarin Pharmaceutical shares in just a few minutes.

BioMarin Pharmaceutical Inc
+$0.77 (+1.00%)

BioMarin Pharmaceutical is a biotechnology business based in the US. BioMarin Pharmaceutical stocks (BMRN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $83.91 – a decrease of 0.39% over the previous week. BioMarin Pharmaceutical employs 3,059 staff and has a trailing 12-month revenue of around $1.9 billion.

How to buy BioMarin Pharmaceutical stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: BMRN in this case.
  5. Research BioMarin Pharmaceutical stocks. The platform should provide the latest information available.
  6. Buy your BioMarin Pharmaceutical stocks. It's that simple.

How has Coronavirus impacted BioMarin Pharmaceutical's stock price?

Since the stock market crash in March caused by coronavirus, BioMarin Pharmaceutical's stock price has had significant negative movement.

Its last market close was $77.3, which is 18.77% down on its pre-crash value of $95.16 and 13.26% up on the lowest point reached during the March crash when the stocks fell as low as $68.25.

If you had bought $1,000 worth of BioMarin Pharmaceutical stocks at the start of February 2020, those stocks would have been worth $849.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $919.87.

BioMarin Pharmaceutical stock price

Use our graph to track the performance of BMRN stocks over time.

BioMarin Pharmaceutical stocks at a glance

Information last updated 2021-07-31.
Latest market close$77.3
52-week range$71.35 - $124.5199
50-day moving average $81.4727
200-day moving average $80.1972
Wall St. target price$107.11
PE ratio 17.4307
Dividend yield N/A (0%)
Earnings per share (TTM) $4.402

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy BioMarin Pharmaceutical stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

BioMarin Pharmaceutical price performance over time

Historical closes compared with the last close of $77.3

1 month (2021-07-02) -9.56%
3 months (2021-04-30) -0.80%

Is BioMarin Pharmaceutical under- or over-valued?

Valuing BioMarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioMarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioMarin Pharmaceutical's P/E ratio

BioMarin Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, BioMarin Pharmaceutical stocks trade at around 17x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.

BioMarin Pharmaceutical's PEG ratio

BioMarin Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7902. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioMarin Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

BioMarin Pharmaceutical's EBITDA

BioMarin Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$54.8 million.

The EBITDA is a measure of a BioMarin Pharmaceutical's overall financial performance and is widely used to measure a its profitability.

BioMarin Pharmaceutical financials

Revenue TTM USD$1.9 billion
Gross profit TTM USD$708.1 million
Return on assets TTM -0.61%
Return on equity TTM 22.39%
Profit margin 43.68%
Book value $23.137
Market capitalisation USD$14.1 billion

TTM: trailing 12 months

How to short and sell BioMarin Pharmaceutical stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "BMRN.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 10.2 million BioMarin Pharmaceutical stocks held short by investors – that's known as BioMarin Pharmaceutical's "short interest". This figure is 3.3% down from 10.6 million last month.

There are a few different ways that this level of interest in shorting BioMarin Pharmaceutical stocks can be evaluated.

BioMarin Pharmaceutical's "short interest ratio" (SIR)

BioMarin Pharmaceutical's "short interest ratio" (SIR) is the quantity of BioMarin Pharmaceutical stocks currently shorted divided by the average quantity of BioMarin Pharmaceutical stocks traded daily (recently around 1.1 million). BioMarin Pharmaceutical's SIR currently stands at 9.39. In other words for every 100,000 BioMarin Pharmaceutical stocks traded daily on the market, roughly 9390 stocks are currently held short.

However BioMarin Pharmaceutical's short interest can also be evaluated against the total number of BioMarin Pharmaceutical stocks, or, against the total number of tradable BioMarin Pharmaceutical stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioMarin Pharmaceutical's short interest could be expressed as 0.06% of the outstanding stocks (for every 100,000 BioMarin Pharmaceutical stocks in existence, roughly 60 stocks are currently held short) or 0.0563% of the tradable stocks (for every 100,000 tradable BioMarin Pharmaceutical stocks, roughly 56 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against BioMarin Pharmaceutical.

Find out more about how you can short BioMarin Pharmaceutical stock.

BioMarin Pharmaceutical's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like BioMarin Pharmaceutical.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

BioMarin Pharmaceutical's total ESG risk score

Total ESG risk: 25.92

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and BioMarin Pharmaceutical's overall score of 25.92 (as at 01/01/2019) is nothing to write home about – landing it in it in the 42nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like BioMarin Pharmaceutical is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

BioMarin Pharmaceutical's environmental score

Environmental score: 0.12/100

BioMarin Pharmaceutical's environmental score of 0.12 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that BioMarin Pharmaceutical is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

BioMarin Pharmaceutical's social score

Social score: 15.87/100

BioMarin Pharmaceutical's social score of 15.87 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that BioMarin Pharmaceutical is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

BioMarin Pharmaceutical's governance score

Governance score: 7.42/100

BioMarin Pharmaceutical's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that BioMarin Pharmaceutical is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

BioMarin Pharmaceutical's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. BioMarin Pharmaceutical scored a 1 out of 5 for controversy – the highest score possible, reflecting that BioMarin Pharmaceutical has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

BioMarin Pharmaceutical Inc was last rated for ESG on: 2019-01-01.

Total ESG score 25.92
Total ESG percentile 42.26
Environmental score 0.12
Environmental score percentile 1
Social score 15.87
Social score percentile 1
Governance score 7.42
Governance score percentile 1
Level of controversy 1

BioMarin Pharmaceutical stock dividends

We're not expecting BioMarin Pharmaceutical to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

BioMarin Pharmaceutical stock price volatility

Over the last 12 months, BioMarin Pharmaceutical's stocks have ranged in value from as little as $71.35 up to $124.5199. A popular way to gauge a stock's volatility is its "beta".

BMRN.US volatility(beta: 0.58)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioMarin Pharmaceutical's is 0.5832. This would suggest that BioMarin Pharmaceutical's stocks are less volatile than average (for this exchange).

BioMarin Pharmaceutical overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.

Stocks similar to BioMarin Pharmaceutical

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site